The company has a market cap of $310.9 million.
Barclays, Cantor and Mizuho Securities served as the underwriters for the IPO.
IN8BIO, INC. provided the following description of their company for its IPO: “We are a clinical-stage biotechnology company focused on developing innovative therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. Gamma-delta T cells are naturally occurring cells in the human immune system that recognize and kill cancerous cells, while possessing a tumor recognition mechanism that protects healthy tissue. We are the first company to advance genetically modified gamma-delta T cells into the clinic, leveraging the powerful and naturally occurring anti-cancer properties of these cells to enable their use in combination with therapeutic administration of chemotherapy. We are conducting two investigator-initiated Phase 1 clinical trials for both of our lead gamma-delta T cell product candidates: INB-200, to treat newly diagnosed glioblastoma, or GBM, and INB-100, to treat patients with leukemia undergoing hematopoietic stem cell transplantation, or HSCT. (Glioblastoma is one of the most aggressive types of cancer that typically starts in the brain or the spinal cord, according to the Mayo Clinic.) “.
IN8BIO, INC. was founded in 2016 and has 7 employees. The company is located at 79 Madison Avenue, New York, New York 10016 and can be reached via phone at (646) 600-6438 or on the web at http://www.in8bio.com/.
Receive News & Ratings for IN8BIO INC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IN8BIO INC. and related companies with MarketBeat.com's FREE daily email newsletter.